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2FOREHEAD LASER DOPPLER AND TRANSCRANIAL DOPPLER
DURING SIMULATED HYPOVOLEMIA.
Kathleen J Samuels, David G. Silverman, and Keith J. Ruskin. Department of Anesthesiology, Yale
University, School of Medicine, New Haven, CT
The present study employed lower body negative pressure (LBNP), a rapidly titratable, safe and reversible
means of inducing simulated hypovolemia, for a comparison of transcranial Doppler (TCD) ultrasound of
the middle cerebral artery and laser Doppler (LD) flowmetry of the forehead microvasculature.
With IRB approval, 9 healthy volunteers (26.3±2.7 years) were monitored continuously with EKG,
noninvasive finger arterial blood pressure (BP), and TCD positioned at the transtemporal window. After a
baseline (Base) period, subjects underwent rapid onset of LBNP to -70 mmHg over the course of 1 minute,
followed by progressive declines of ~10 mmHg until lightheadedness or had a BP decline >20% of baseline
BP. Changes in the peak (systolic) and trough (diastolic) values with each heart beat were analyzed at Base,
at approx. 30 seconds prior to the onset of lightheadedness (Presympt) and at onset of symptoms (Sympt).
In the 6 subjects who subsequently became lightheaded, forehead LD flow decreased by 10.9±11.7% at
Presympt (p=NS for interphase difference). It then decreased by an additional 20.4±18.7% with the onset of
lightheadedness (p=0.035 for Presympt vs. Sympt). Peak TCD readings decreased by 29.3±9.7% from Base
to the time of the Presympt measurement (p=0.001); they then increased by 4.1±12.9% with the onset of
Sympt (p=NS). In the 2 subjects who remained asymptomatic, LD did not change significantly in the
Presympt and Sympt phases where Sympt was the time when the study was terminated because the BP
cutoff was reached. In these asymptomatic subjects, the TCD flow velocity declined progressively.
The present findings suggest that monitoring of the microvasculature in the distribution of the carotid
arteries provides a better indication of changes in perfusion associated with lightheadedness than
measurement of velocity at the middle cerebral artery. The discordance between LD and TCD is consistent
with autoregulatory mechanisms at the level of the forehead microvasculature that have previously been
reported in the context of systemic administration of phenylephrine.
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5Introduction
The goal of the present study is to determine whether there is preservation of blood flow
in the middle cerebral artery and in the microcirculation of the forehead during
hypoperfusion produced by inducing simulated hypovolemia. Up to a point, the body is
able to compensate for blood loss and maintain a normal mean arterial blood pressure and
heart rate via local and systemic autoregulation of the vasculature. However, the presence
of a normal systemic blood pressure during hemorrhage implies that vasoconstriction is
depriving some organ or organ system of its blood supply.1 Hypotension and tachycardia
are late findings in hypovolemic shock and “do not mark the beginning of circulatory
failure, but rather represent the beginning of decompensation.”1 Hypovolemic shock
occurs due to a decrease in intravascular volume, which causes a decrease in preload.
Decreased preload leads to diminished stroke volume (SV), and thus decreased cardiac
output (CO). Systemic vascular resistance (SVR) is typically increased in the setting of
hypovolemic shock, as the vasoconstriction acts to maintain blood flow to vital organs
(brain, heart, etc.).
Central microcirculation is preserved during vasoconstrictive challenges using
phenylephrine,2-4 the cold pressor test5 and nicotine. High-frequency oscillations were
noted in blood flow through the forehead microvasculature during these vasoconstrictive
challenges,2-5 although the significance of these oscillations has yet to be determined. For
comparison of the forehead microcirculation laser Doppler (LD) flow to transcranial
Doppler (TCD) velocity in the middle cerebral artery, progressive lower body negative
pressure (LBNP) is a good model to use for impending circulatory collapse. LBNP
6induces physiological changes comparable to 70-degree head-up tilt,6 passive standing6
and controlled hemorrhage,6 but has advantages over other experimental methods.
Previous studies have shown that lower body negative pressure accurately simulates
blood loss and produces hemodynamic and autonomic responses consistent with central
hypovolemia.6-17 Depending upon the speed of the change in lower body negative
pressure, compensation for the central volume loss may be observed at varying levels of
the circulation.6, 15 Our focus was on a fast LBNP protocol and the cardiovascular and
neural reflex responses seen as the body quickly compensates for an acute loss of central
volume. Our group postulates that the oscillations previously seen in the forehead
microcirculation2-5 could be related to the autoregulation of cerebral blood flow, given the
common neural and vascular innervations of the forehead and cerebral hemispheres via
the internal and external carotid arteries.18
7Background
Cerebral Circulation:
The Circle of Willis represents the communicating system of arterial blood flow to the
brain. The two internal carotid arteries and two vertebral arteries deliver the main blood
supply to the brain. The vertebral arteries converge to form the basilar artery. The six
major vessels supplying blood to the cerebral cortex are the left and right anterior, middle
and posterior cerebral arteries (See Figure 1).
 
Figure 1. Circle of Willis. Left, two-dimensional representation of the communicating system of cerebral
blood flow. Right, three-dimensional representation of the solution to the incompressible Navier-Stokes
equations (INS3D) for flow through the Circle of Willis (Left, from Franco Folino, 2007; Right, from
http://www.nas.nasa.gov/Resources/Applications/applications.html)
8As intracranial arteries penetrate into the gray matter, they become progressively smaller
and undergo characteristic changes (i.e. loss of smooth muscle) becoming arterioles and
finally resulting in the formation of capillaries.19 These capillaries have a tight endothelial
layer (forming the blood-brain barrier) and are surrounded by pericytes and astrocytes.19
Pericytes can directly induce changes in capillary diameter.20
Endothelium of both the systemic and cerebral vessels is said to have a complex and
fundamental role in regulation of circulation and homeostasis of the local vessel.21
Endothelium in cerebral vessels forms the blood-brain barrier via tight junctions, thus
selectively prohibiting certain substances from entering the cerebral tissue. Cerebral
vascular resistance is regulated on a local level via many substances produced by the
endothelium or that act on the endothelium.22, 23 Acetylcholine, adenosine diphosphate,
adenosine triphosphate, and bradykinin are known to induce dilation of the cerebral
vasculature via actions on the endothelium.22, 23 These substances can cause dilation when
they activate G-coupled protein receptors present on endothelium.22, 23 They also lead to
the production of prostanoids, endothelium-derived hyperpolarization factor, or nitric
oxide, which induce vasodilation.22, 23 Alternatively, vasoconstriction can be induced via
other factors with effects on endothelium, including endothelin-1, thromboxane-A2 and
prostaglandin F2α.19
Additionally, the cerebral vascular bed is innervated by the autonomic nervous system
(See Figure 2).19, 24 Extracerebral arteries, located in the pia mater, are innervated by
sympathetics originating in the superior cervical ganglion (SCG), parasympathetics
9originating in the sphenopalatine (SPG) and otic ganglia (OG), and send sensory
information via neurons directed toward the trigeminal ganglion (TG).19, 25 When the
extracerebral vessels enter the brain parenchyma, it is said that they lose this
innervation.19 The intracerebral vessels encounter neurons that are specific to the brain:
subcortical neurons of the basal forebrain, raphe nucleus, thalamus, and locus coeruleus,
and interneurons (See Figure 2).19 Most of the perivascular nerves interact with the
vessels via astrocytes that typically surround the vessels, rather than by direct contact.19
These neurons can regulate the diameter of the microvessels by releasing
neurotransmitters (acetylcholine, serotonin, norepinephrine, etc.) that interact directly
with the smooth muscle or endothelium of the vessels, or with specific receptors on the
astrocytes, and lead to vasoconstriction or vasodilation.25
Figure 2. Innervation of extracerebral and intracerebral arteries. Arteries in the pia mater receive
sympathetic innervation from the superior cervical ganglion (SCG), parasympathetic innervation from the
sphenopalatine (SPG) and otic ganglion (OG), and sends sensory information to the trigeminal ganglion
(TG).19 Intracerebral arteries are innervated by subcortical neurons originating from the locus coeruleus,
raphe nucleus, basal forebrain, and thalamus.19 Nerve endings can directly contact a vessel or can contact
interneurons or astrocyte bodies to affect the vessel.19 (From Franco Folino, 2007)
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Cerebral Autoregulation:
Cerebral Autoregulation (CA) is the ability of the cerebral vasculature to independently
regulate and maintain cerebral blood flow despite changes in systemic arterial blood
pressure, within a limited range of mean arterial pressures (MAP) – for example, 60-
140mmHg.19, 26 Cerebral arteries of all sizes can participate in CA, but principally
arterioles less than 100 to 250 µm are involved.19 Static autoregulation refers to steady-
state changes in cerebral blood flow in response to progressive, gradual changes in blood
pressure.27 Dynamic autoregulation refers to the rapid modifications in cerebral blood
flow in response to abrupt changes in arterial blood pressure, over the course of
seconds.27 Dynamic cerebral autoregulation may have different mechanisms of action
than static autoregulation.27
Four pathways potentially mediate cerebral autoregulation: myogenic, metabolic,
neurogenic,28 and endothelial function.21 Smooth muscle cells of the arterioles have an
intrinsic ability to induce vasoconstriction in response to elevated cerebral blood
pressure,29 increasing the resistance and limiting the amount of pressure to which the
cerebral tissue is exposed. Changes in arteriolar resistance occur in the setting of
modifications of local or systemic metabolism,30 including changes in concentration of
oxygen and adenosine. The concentration of CO2 also affects vessel diameter, with
hypocapnia leading to vasoconstriction and hypercapnia leading to vasodilation.31
Cerebral vessels are innervated by both sympathetic and parasympathetic nerves.32
Sympathetic nerves are thought to be the principal autonomic neurogenic modifiers of
cerebral blood flow.33 The sympathetic nervous system acts via tonically active34
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norepinephrine and neuropeptide Y secretion,33 which leads to vasoconstriction. Despite
potential vasodilator effects of brain vessels by the parasympathetic nervous system, via
mediators such as vasoactive intestinal peptide, acetylcholine and nitric oxide, current
literature states that the parasympathetic nervous system does not play a relevant role in
cerebral autoregulation.24 Neurally-mediated control of autoregulation may be more
effective during dynamic than static autoregulation.35 Endothelium influences vessel
diameter as it releases mediators, such as nitric oxide, and as it modulates the three
mechanisms just listed, inducing constriction or dilation.21
In response to changes in systemic blood pressure, the diameter of cerebral arteries
change in order to maintain a constant cerebral blood flow.19 Cerebral blood flow is
directly proportional to the blood pressure and inversely proportional to the cerebral
vascular resistance.19 Total cerebral blood flow at rest is approximately 15 to 20% of total
cardiac output, or about 800 mL/min.27 Efficient autoregulation requires synchronized
vasoactive mechanisms in the pial and intracerebral arteries.27 Pial vasoconstriction limits
the ability of the downstream intracerebral arteries to vasodilate.27 If the intracerebral
arteries vasodilate because of the direct effect of surrounding neurons, then this
vasodilatory stimulus is propagated retrogradely to the pial arteries.36
Cerebral blood flow is dependent upon the pressure gradient across the cerebral
vasculature19; the pressure gradient decreases as the arterial blood pressure is rapidly
reduced,37 thus the cerebral blood flow is also reduced. During acute changes in systemic
blood pressure (BP), the cerebral blood flow should remain stable if dynamic CA is intact
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(See Figure 3).37 If there is a precipitous fall in BP, however, there can be a transient,
acute drop in cerebral blood flow.38 In this setting, when dynamic CA is intact the
recovery of the cerebral blood flow occurs despite continually depressed BP37 because of
the reflex modulation of cerebrovascular resistance.19 Impairment of CA, alternatively,
leads to a continued fall in cerebral blood flow that follows the trend of MAP.37
Prodromic symptoms occur when cerebral blood flow falls below 40 - 50% of baseline
levels; loss of consciousness typically occurs after 8 to 10 seconds of interrupted cerebral
blood flow.27, 39
Regardless of the underlying disease process in syncope, the ultimate cause of loss of
consciousness is “insufficient cerebral perfusion, with a critical reduction in blood flow
to the reticular activating system, the neuronal network of the brainstem responsible for
maintaining consciousness.”19 Symptomatic orthostatic hypotension that is associated
with decreased cerebral blood flow velocity (CBFV) may occur because of a transient
reduction in perfusion pressure,37 a paradoxical increase in cerebral vascular resistance
elicited by sympathoexcitation or hypocapnia,38, 40 or a combination of factors.37
Occasionally, there is a paradoxical increase in cerebral vascular resistance in response to
a decrease in systemic blood pressure, which leads to a critical reduction in cerebral
blood flow and neurally mediated syncope.19 Lower CBFV during orthostatic
hypotension may be the physiological reason for symptoms, but the symptoms can occur
despite the maintenance of cerebral autoregulation.37
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Figure 3. Flow-pressure curve of the cerebral circulation. Cerebral autoregulation maintains a constant
cerebral blood flow through a range of normal mean arterial pressures (60-140 mmHg), despite changes in
systemic blood pressure. When the MAP falls below 60 mmHg, cerebral perfusion decreases proportionally
to MAP. When MAP exceeds 140 mmHg, cerebral perfusion increases proportionally to MAP. (From
Franco Folino, 2007)
The flow-pressure curve of cerebral circulation is not fixed.19 An individual’s baseline
arterial blood pressure and chronic diseases can induce a shift of the curve to the left or
right in order to protect the cerebral tissue.41 For example, hypertensive patients have a
curve that is shifted to the right41 (See Figure 4) because of static autoregulation. This
right shift allows for constant cerebral blood flow, and avoidance of hyperperfusion and
excessive pressures, at higher systemic blood pressures.19 A right shift of the curve leaves
a patient more susceptible to declines in cerebral blood flow (and potentially an ischemic
event) if the systemic blood pressure falls below the lower limit of the range in which
autoregulation can occur.19 In patients with hypotension, static autoregulation leads to a
left shift of the flow-pressure curve.41 Hypotensive patients maintain a constant cerebral
blood flow, despite lower than normal systemic blood pressures.41 These hypotensive
patients are at risk of damage to the cerebrovascular endothelium and disruption of the
blood-brain barrier in the setting of hypertension.42
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Figure 4. Flow-pressure curve of the cerebral circulation shifts in hypertensive and hypotensive patients.
There is a right shift of the curve in patients with hypertension, because the static cerebral autoregulation
acts to maintain cerebral blood flow at a constant level, despite higher systemic blood pressures. In
hypotensive patients, the curve shifts to the left and static autoregulation acts to keep cerebral blood flow
constant despite lower systemic blood pressures. (From Franco Folino, 2007)
In addition to hypertension and hypotension, there are many pathologic conditions that
cause changes in CA.19 In ischemic stroke, dynamic and static autoregulation are
impaired.43 Carotid artery stenosis causes impaired CA that is a marker for patients at
higher risk for stroke,44 and which is reversible upon endarterectomy or stenting.45 Head
injury,46 focal ischemia47 and subarachnoid hemorrhage48 also affect CA. Aging, on the
other hand, is associated with lower cerebral blood flow and velocity,49 but is not
associated with a decline in CA.50
Discovery of Oscillations in the Microvasculature
Heart Rate Variability:
 Heart rate variability (HRV) was first noted in the 18th century when Stephen Hales
carried out experiments that led to quantitative measurements of arterial blood pressure,
which could then be compared to the respiratory cycle and beat-to-beat intervals.51
Oscillations in signals (flow, velocity, electrical conduction, etc.) are also known to exist
15
within the cardiovascular system. The variation noticed in the beat-to-beat interval has
been considered clinically normal but its importance was first emphasized in fetal
monitoring.52 Loss of fetal HRV is a sign of distress and is an indication for prompt
delivery.52
Beat-to-beat variations represent the dynamic response that is occurring in the
homeostatic mechanism when there are perturbations in the cardiovascular system.52 The
variations in arterial and venous blood pressure stem from changes in intrathoracic
volume and pressure during the respiratory cycle and also from changes in the peripheral
vascular resistance when local autoregulation of blood flow occurs at the tissue level.52
These changes are sensed by a variety of chemoreceptors and baroreceptors52 that in turn
modify the heart rate, electrical conduction and contractility of the heart, and arterial and
venous tone in order to maintain homeostasis.52
Spectral analysis breaks a signal into its component waveforms. The sinusoidal
components of an electrocardiogram (ECG) can be described as very-low-frequency
(VLF; <0.04 Hz), low-frequency (LF; 0.04-0.10 Hz) and high-frequency (HF; >0.10 Hz)
spectral components. The heart rate power spectrum is regulated at each frequency by
one or more control mechanisms that either induces or amplifies the oscillation. VLF
oscillations are attributed to the sympathetic nervous system, thermoregulation and
regulation by the renin-angiotensin system.52-54 LF oscillations are mediated by both
sympathetic and parasympathetic inputs, but also by baroreceptor reflexes.52, 53 HF
oscillations are attributed to the parasympathetic nervous system, but are also related to
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respiratory rate.52-54 The parasympathetic response time is much shorter than that of the
renin-angiotensin or sympathetic nervous systems.53 Cholinergic activity is known to be a
predominant component of heart rate fluctuations. 55, 56
The reason for the lack of sympathetic control at higher frequencies has been elucidated
by Stauss, HM et al., with a series of experiments on rat vascular smooth muscle cells53.
These experiments demonstrated that periodic depolarization was possible at up to 0.5 Hz
when K+ was used, but that when phenylephrine was the depolarizing agent, the cells
could not contract periodically any faster than 0.1 Hz; tonic contraction occurred at
frequencies higher than 0.5 Hz and 0.1 Hz, respectively53. This implies that smooth
muscle is physically capable of contracting more rapidly than 0.1 Hz, but the rate-
limiting step is the sympathetic activation of the smooth muscle53. The slow adrenergic
signal transduction system accounts for the sympathetic component being limited to VLF
and LF oscillations53.
VLF, LF, and HF oscillations have been discovered in the heart rate52, blood pressure55,
and microvascular flow.57 There is sympathetic involvement in the oscillatory control of
the blood pressure and microcirculation55, 57. During times of cardiovascular stress,
sympathetic control of HRV increases and the parasympathetic contribution is
diminished56. As a person’s ability to continue to mount the autonomic response
diminishes, there is sympathetic withdrawal and parasympathetic tone predominates56. In
the setting of trauma or hypovolemia, a high parasympathetic to sympathetic ratio in the
HRV power spectral analysis is a predictor of impending death56. The sympathovagal
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balance in the HRV has been used as an indicator to try to predict mortality in many
clinical conditions.56, 58
Cold Pressor Test:
During the cold pressor test, the subject places his or her hand in ice water (4 degrees
Celsius), producing reflex systemic vasoconstriction. In a study by Awad et al. in 2001,
plethysmographic signals at the ear was not significantly changed while a significant
decrease was seen in the finger signal.5 The plethysmographic amplitude depends on
systemic intravascular pulse pressure (ΔP) and the distensibility (D) of the vascular wall5,
59. This relationship is similar to that of blood volume pulsations (ΔV) seen during
flowmetry, where ΔV = Δ P x D. 5, 59 The finger plethysmographic amplitude is
determined by the autonomic nervous system,5, 60 because of the high density of
adrenergic receptors at this site.
In the finger, the large sympathetic response to the cold pressor test is mediated by the a-
adrenergic receptors that line the cutaneous vessel walls.5 It is therefore postulated that
the finger can provide valuable information about changes in sympathetic tone.5 Whereas
changes in the amplitude of the ear plethysmograph may more closely reflect changes in
pulse pressure.5 Awad et al., in 2001, noted that the changes in the plethysmographic
signal and the blood pressure are correlated and postulated that there is a generalized
synchronization of oscillations in the low frequency range in different areas of the body,
i.e. the finger and the ear.5, 61
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Laser Doppler:
Cutaneous LD flowmetry uses a noninvasive fiber optic probe to quantify the phase shift
of laser light induced by moving red blood cells in the 10-60 capillaries under a 1-mm2
area of skin.2, 3 The laser Doppler probe must be affixed to a single site throughout a
given study because movement and positioning of the probe will affect the results.2 The
probe can detect the concentration of moving red blood cells (CMBC) and red cell flux
(CMBC times red blood cell velocity) in the arteriolar-capillary network at a depth of 500
to 700 nm below the surface of the skin.2 CMBC is primarily sensitive to local changes in
vessel caliber and hematocrit.2 Red cell flux is more sensitive than CMBC to RBC
velocity.2 LD can identify a microsvascular response to a vasoconstrictive stimulus and,
thus, provides monitoring of changes in cutaneous perfusion.2
Changes in cutaneous microvascular flow may be a surrogate marker for changes in
perfusion of vital organs.2 Importantly, atherosclerotic coronary arteries are sensitive to
α-adrenoreceptor agonists, cold pressor testing and mental stress.2 Toda et al. examined
the patterns of blood flow and sympathetic nerve activity of vital organs during
nonpulsatile cardiopulmonary bypass and noted a decrease in renal blood flow (with a
concurrent increase in sympathetic nerve activity), but no change in blood flow to the
heart or brain.54, 62 The Toda group proposed a possible vagally-mediated mechanism by
which certain critical organs maintain perfusion during increased sympathetic nervous
system activity.54, 62
Prior to the availability of LD flowmetry, it was postulated that there is a process at the
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microcirculatory level that maintains perfusion during arterial vasoconstriction.3, 63
Discovery of nonadrenergic neural elements 64 and cholinergic receptor activity at the
precapillary level,65 acetylcholine modulation of perivascular adrenergic receptors66 and
of acetylcholine-induced release of endothelium-dependent vasodilatory factors,67 led to
the development of a theory that the parasympathetic nervous system was involved in the
regulation of microvascular blood flow.3
The Effects of Phenylephrine on Forehead Laser Doppler:2
Microvascular smooth muscle cells oscillate out of synchrony with neighboring cell
populations when not under extrinsic (autonomic) regulation.3 Out of phase oscillations
damp the laser Doppler signal, which is sensitive to the phase relationships of underlying
capillaries.3 Under neural control, oscillation of the capillaries of the same branching
order become synchronized, resulting in a stronger LD signal.3 Resistance of the vascular
bed declines as more capillaries are recruited to synchronous oscillation, because the
resistance of a vessel (or vascular bed) whose diameter varies sinusoidally is lower than
that of a constant-caliber vessel with the same average diameter.3, 68
Almost 70 years ago, Hertzman and Dillon reported that there is a specific distribution of
vasoconstriction within the body in response to a vasoconstrictive stimulus. 69 Regions
innervated more densely by adrenergic fibers (i.e. finger) respond with decreased
perfusion while more central regions (i.e. forearm, forehead) seem to have maintained
blood flow during a vasoconstrictive challenge. 3, 69 While the parasympathetic nervous
system has been shown in blood pressure and heart rate oscillations, the peripheral
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vasculature has been labeled as devoid of parasympathetic input.4
In a study by Silverman et al., LD probes were attached to the palmar surface of the
fourth finger and the volar surface of the forearm.2 These two sites have distinct vascular
anatomy, innervation, function and responsiveness to autonomically active substances.2
Phenylephrine was infused at a rate of 0.4, 0.8 and 1.6 ug/kg/min for 10-minute
intervals.2 The finger LD showed a decrease in flux and CMBC during all of the
infusions, while the forearm LD revealed a variable response to the infusions and
achieved a statistically significant increase in flux and CMBC only during the 0.4
ug/kg/min infusion.2 The decreased LD flow in the finger is consistent with the predicted
results, given the rich concentration of α1-adrenoreceptors and a vasoconstrictive
stimulus (phenylephrine).2 However, the apparent vasodilatory response at the forearm
during the lowest rate of infusion of the α1-receptor agonist, and variable flow during the
higher rates of infusion, leads one to believe that a homeostatic response may be
occurring, which allows for both vasoconstriction and vasodilation.2 This vasodilation in
the forearm, at the time of a decrease in heart rate, potentially represents vagally
mediated baroreceptor activity and occurs even in the absence of a change in blood
pressure. 2 This theory is supported by data from head-down tilt studies that show an
increase in forearm blood flow with concurrent decrease in heart rate.70 Additionally,
there is evidence that phenylephrine can directly affect baroreceptors, even in the absence
of a pressure change.71, 72
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Cholinergic Oscillatory Control in the Forehead Microvasculature:
In an unpublished study by Silverman et al.•, the disparity in forehead and finger blood
flow was monitored using laser Doppler flowmetry, during which subjects consumed
nicotine lozenges to produce vasoconstriction. During this study, nine subjects were
monitored and two of these subjects developed symptoms of lightheadedness and nausea.
All nine of the subjects had signs of vasoconstriction and each one developed oscillations
of the forehead laser Doppler signal in the high frequency range with exposure to the
nicotine. In the two subjects who became lightheaded, the oscillations at 0.13 Hz +/-0.3
Hz disappeared immediately prior to the onset of the symptoms. These results provided
supportive evidence for the idea that the oscillations in the microvasculature function in a
protective or homeostatic manner.
In a subsequent study, Silverman et al. investigated the microvascular blood flow at the
finger and forehead during systemic phenylephrine and atropine infusions.3 During
phenylephrine infusion, there was a decrease in blood flow to the finger and maintenance
of flow at the forehead site of laser Doppler.3 The autonomic activity noted in the spectral
analysis of the finger during phenylephrine infusion was primarily in the low-frequency
(sympathetic) range.3 Alternatively, the primary peak in spectral power at the forehead
was in the high-frequency (parasympathetic) range at 0.12-0.18 Hz,3 consistent with
cholinergic oscillatory control (termed COCVASC by Silverman et al., 2001).3 At the point
in the study during which atropine was added to the phenylephrine infusion, the high-
frequency oscillations in the forehead disappeared.3 Because phenylephrine is known to
                                                 
• Personal communication with investigators
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activate a parasympathetic homeostatic response at the level of the heart, the investigators
concluded that it could induce a parasympathetic homeostatic response at the level of the
microcirculation.3 Additionally, because atropine is an anti-cholinergic medication and it
inhibited the oscillations in the microcirculation, a parasympathetic process may mediate
these oscillations.3
Prior to the 2001 Silverman study, there was no discussion of parasympathetic
involvement in the microvascular oscillations. The HF oscillations that have been
documented to occur in the peripheral microvasculature had previously been attributed to
mechanical transduction of respiration-related changes in heart rate and stroke volume.55,
73 Acetylcholine played a role in thermal reflexes and “local functional hyperemia,” 4, 65
but acetylcholine was not considered to be an important vasomotor neurotransmitter. 65
The prevailing theory since that time has been that the parasympathetic nervous system is
not involved in regulating peripheral vascular resistance.74 The autonomic innervation of
the peripheral vasculature is believed to be almost entirely sympathetic,55, 73, 75 which
would lead to low frequency oscillations on spectral-domain analysis.
The Silverman et al. 2002 investigation4 was designed to determine whether the
oscillations in the microvasculature originate in the microcirculation or if they are the
result of transmitted changes in the diameter of more proximal vessels. Previously,
investigators have postulated that the high frequency oscillations in the peripheral
microvasculature are due to mechanical transmission of oscillations from the heart rate,
cardiac stroke volume and systemic blood pressure.55, 73 Additionally, high frequency
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microvascular oscillations in the have been associated with respiration in the same way
that HRV is associated with respiration.55, 73 There are direct drug effects on
microvascular oscillatory activity and indirect baroreceptor-mediated reflexes at the level
of the microvasculature.75 The microvasculature has been considered “relatively passive,”
as it does not have a significant amount of adrenergic innervation.55, 73, 75
To further explore the nature of the oscillations in the forehead laser Doppler signal,
Silverman et al. infused phenylephrine, followed by atropine, into 15 healthy volunteers4.
This study showed that the most prominent oscillatory peak in the forehead LD signal
was at 0.14 +/- 0.2 Hz and that this peak is atropine sensitive,4 consistent with earlier
work3. Spectral-domain analysis of the R-wave to R-wave interval (from the ECG)
revealed an oscillatory peak at 0.2 Hz and this peak was also atropine sensitive4
(consistent with previous HRV studies that show predominant cholinergic control of
heart rate).52 The respiratory frequency, systemic pressure and systemic flow also had the
most power at 0.2 Hz and they did not have a peak at 0.14 Hz.4 As expected,
phenylephrine did not cause atropine-sensitive oscillations in the finger laser Doppler
signal.4 The forehead LD signal and R-wave to R-wave interval signal had distinct and
non-overlapping predominant peaks at 0.14 and 0.20 Hz, respectively.4 The changes in
amplitude of the signals were not proportional and the signals oscillated out of synchrony
from one another.4 Additionally, the forehead LD signal did not have overlapping peaks
with systemic blood flow or pressure in the power spectral analysis.4 These discrepancies
lead one to believe that there is no physical, down-stream relationship between the heart
rate oscillations/blood pressure oscillations and the forehead microvascular oscillations.4
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Furthermore, these data support the theory that the oscillations are parasympathetic in
nature.4
Additionally, forehead LD probes placed at different sites on the forehead transmit
signals from microvessels that were oscillating out of synchrony from neighboring
vessels.4 In a small study, a topical local anesthetic was applied to the forehead of four
subjects 45 minutes prior to LD probe placement. Forehead oscillations in the
microvasculature were eliminated by the local anesthetic.4 These two additional
investigations support the proposal that the oscillations in the microvasculature that occur
during phenylephrine infusion are a local, peripheral phenomenon and are not the result
of transmission from proximal sites.4 The cholinergic oscillatory control of the
microvasculature (COCVASC)3 may function to maintain microvascular homeostasis.4
Synchronous Rhythmical Vasomotion in the Microvasculature During Nonpulsatile
Cardiopulmonary Bypass:
Traditional understanding of microvascular oscillation has been that only low-frequency
oscillations (0.04 – 0.10 Hz) originate from the microcirculation and that high-frequency
oscillations (>0.12 Hz) are transmitted from changes in stroke volume caused by
respiration or through mechanical transmission from more proximal vessels.57 In 2002,
Silverman et al used approximate entropy (ApEn) to determine whether oscillations arise
in the absence of cardiac and respiratory activity, in the setting of nonpulsatile
cardiopulmonary bypass (NP-CPB).54 Approximate entropy is a tool that evaluates the
overall complexity of a signal; as the oscillations become less chaotic and more regular,
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the approximate entropy decreases.54 NP-CPB was associated with the development of
high-frequency forehead oscillations (0.13 +/- 0.03 Hz) and low-frequency finger
oscillations (0.07 +/- 0.02 Hz) in the LD flow.54 In addition to increased power in the
high-frequency spectral domain analysis, as the NP-CPB proceeded, there was a decrease
in approximate entropy.54 The decrease in entropy was because of an increase in
synchronization of oscillations in the microvasculature.54
The emergence of organized, high-frequency oscillations in the microvasculature during
NP-CPB may have implications about the local, and even systemic, vasoregulatory
mechanisms.54 This potentially homeostatic mechanism occurs at the level of the
microcirculation in the setting of a vasoconstrictive challenge and also during systemic
depulsation and may protect the body’s vital organs from ischemia.54 HF oscillations have
been demonstrated in numerous cholinergically-rich locations within the body, including
the brain76, viscera77, and centrally located skin (head, trunk, proximal arm).3, 4, 78, 79 HF
oscillations could be induced with hyperventilation78, arousal79, cerebral
vasoconstriction76 and transient arterial occlusion.80 Absence of HF oscillations is
associated with poor outcome in diabetic wound healing.81 It has therefore been proposed
that HF oscillations could represent a cholinergically-mediated homeostatic mechanism
that preserves blood flow during vasoconstrictive challenges.54
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Study Design
Lower Body Negative Pressure (LBNP):
Studies involving the local application of reduced atmospheric pressure were first
conducted in 1841 by Junod,6 who used reduced pressure to draw blood away from
diseased organs, cause a severe, localized hyperemia, and also to induce syncope.82 This
induced syncope was used to create a “satisfactory state for the conduct of surgery.”6 By
the mid-1960’s, LBNP was introduced to medical research by Stevens and Lamb.15
LBNP is used to study orthostatic stress,83 cardiovascular response to hypovolemia11 and
the ability of baroreceptor reflexes to change peripheral vascular resistance during
simulated hemorrhage.16 Blood pressure regulation84 and the effects of physiologic and
pharmacologic interventions on cardiovascular reflexes12 can also be examined. LBNP
has been used clinically to create dry operating fields during surgery6, 15 and also to
promote a foot-ward shift of blood after hip replacement.85 LBNP has been used to
reverse the orthostatic intolerance caused by spaceflight, bed rest and head-down tilt.86
LBNP can be used to simulate gravity during exercise in sub-gravity conditions and has
also been employed to simulate partial gravity environments, like the Moon or Mars.87
LBNP does not rely on the earth’s gravitational field, and may therefore be useful for
preventing complications of spaceflight.6 Astronauts in spaceflight can use LBNP not
only to reverse orthostatic intolerance, but also to prevent musculoskeletal
deconditioning, neuromotor dysfunction and to maintain bone health.88 LBNP is also used
experimentally during vertical acceleration on high-performance aircraft.8 There are a
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multitude of other uses for LBNP that have been reviewed thoroughly in the articles by
Goswami et al, 200815 and Wolthuis et al, 1974.6 LBNP is useful for testing autonomic
function89 during simulated hypovolemia.
LBNP is used as a model for central hypovolemia because of its noninvasive,
reproducible, and easily reversible nature.6, 11, 15 During supine LBNP, a subject lies
horizontally with his/her legs and pelvis inside of the LBNP chamber. A seal is created
after which a vacuum pump decreases pressure inside the chamber while a barometer
measures the internal pressure. The hemodynamic effects of LBNP are similar to those
following +Gz loading,90 passive stand,6 controlled hemorrhage6 and 70 degree head-up
tilt.6 LBNP is less expensive than a human centrifuge, but remains an accurate way to
study the effects of G loads on the cardiovascular system.7, 91 Compared to passive
standing, LBNP provides a better model for central hypovolemia because it allows for
quantification of approximate blood “loss” or pooling, and there are progressive stages of
severity. Large volume controlled hemorrhage is no longer performed in unanaesthetized
humans for ethical reasons, but there are sentinel papers that review outcomes from these
types of experiments.92 70-degree head-up tilt and LBNP both induce central
hypovolemia, blood pooling and decreased cardiac output. However, 70-degree head-up
tilt and LBNP produce different physiological responses to the challenges and LBNP
provides a more controllable, progressive environment.
The body responds to LBNP with similar cardiovascular and neurohumoral reflexes as
during acute hemorrhage because the mechanism by which LBNP acts leads to a similar
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decrease in venous blood return, preload, stroke volume and cardiac output.11 LBNP
causes reproducible physiologic changes, including specific hemodynamic and
neurohormonal reflexes93 in response to induced hypotension.6, 11, 15 Changing the level of
negative pressure adjusts the degree of hypotension.6, 11, 15 LBNP reduces thoracic blood
volume, decreases central venous pressure, diminishes stroke volume and cardiac output,
and increases peripheral vascular resistance while causing blood to pool.11, 94 LBNP
decreases preload, resulting in decreased stroke volume via the Frank-Sterling
mechanism.11 Depending on the magnitude of the pressure used and the speed of the
progression of application of the LBNP, the physiologic responses to LBNP will be
different.6, 15, 95 During –30 to –50 mmHg of LBNP 0.5-1.0 liter of blood is pooled in the
lower body.6 With higher pressures more blood tends to pool, with an estimate of 1.5L
pooling with the use of –80 mmHg LBNP.96
There are three distinct phases of the hemodynamic response to acute central
hypovolemia.11 Phase I involves the maintenance of arterial blood pressure despite falling
cardiac output, mediated by baroreceptor-reflex generated vasoconstriction and sustained
tachycardia.92 Phase II occurs when the cardiac output falls below a critical value (50-
60% of resting cardiac output or 30% of blood volume) and vasoconstriction fails and is
marked by bradycardia and hypotension.92 Phase II is associated with fainting. During
phase II there is increased parasympathetic and decreased sympathetic activity.11 In
severe hemorrhage, a third phase can occur, during which tachycardia reappears and is
accompanied by inability to maintain microvascular circulation.97-99 This third phase is
associated with ischemia, cellular dysfunction and death.97-99 These three stages of
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hemorrhagic shock are also described in subjects undergoing LBNP.100
The greater the amount of LBNP applied to a subject, the greater the amount of pooling
of blood in the lower extremities.11 Also, with a larger amount of LBNP, there will be a
more substantial decline in a subject’s central venous pressure.11 The CVP generally
declines by 3 mmHg at -10 mmHg LBNP and by 7 mmHg at -60 mmHg LBNP, with a 1
mmHg decline in CVP per -10mmHg progression in LBNP.11 However, the degree of
hypotension and lower extremity blood pooling experienced by each subject will vary at
a given LBNP based on the subject’s individual response to the challenge.101
The duration and speed of onset of negative pressure, as well as the size of the decrease,
affect the physiological response of a given subject to LBNP.102 LBNP that is applied for
a short amount of time and is advanced quickly will facilitate study of the sympathetic
and parasympathetic circulatory reflexes in response to acute central hypovolemia.103
Brief exposure to LBNP of less than 15 minutes total104 will not cause hormonal
compensation to the hypovolemia105 and will allow for a study that manipulates only the
neural and baroreflex systems.15 Most of the cardiovascular effects due to changes of the
LBNP occur in the first 3 minutes after the change.106 Longer exposures to LBNP, of 20
minutes or more, lead to more complex neurohormonal responses.95 Low pressure (10
mmHg) LBNP for 60 minutes leads to a decrease in central, splanchnic and forearm
blood flow,107 while the mean arterial pressure and pulse pressure remain unchanged.
The change in blood flow without a concurrent change in blood pressure is thought to be
secondary to sympathetic108 and renin-aldosterone system90 activation.
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When LBNP is adjusted in increments – steps of a varying pressure after a set amount of
time – there is a pressure-dependent change in the neural and hormonal (specifically,
renal) systems,109 cardiac preload reduction,110 vasoconstriction and tachycardia.111
Graded LBNP which is gradually and continuously increased, rather than in steps, can
reduce CVP in a stepwise fashion, which enhances baroreceptor sensitivity.112 Graded
LBNP has been used to study the integrity of vasomotor reflexes.90 Using a moderate to
strong level of LBNP with a “ramp” of the pressure (rapid, graded increase), allows for
the study of cardiovascular and autonomic responses to moderate to severe stress.15
Using the LBNP model for impending cardiovascular collapse, it is possible to safely
induce progressive decreases in cerebral perfusion to the point of presyncope during
which subjects feel lightheaded, dizzy, sweaty, or nauseous. The cardiovascular response
to this physiologic challenge consists of reflexes that attempt to maintain arterial pressure
and cerebral perfusion.113 When these compensatory reflexes are overwhelmed,
circulatory collapse occurs leading to decreased perfusion of the brain with associated
loss of consciousness.6 At the end of the study, the blood that has pooled in the lower
body will be returned rapidly as the suction is decreased. This restored blood volume
leads to resolution of symptoms and normal circulatory hemostasis.6
Transcranial Doppler (TCD) Ultrasound:
When a wave front strikes a moving object, it is reflected back towards its source, but its
frequency is shifted. The change, or shift, in the frequency between the incident and
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reflected waves is known as the Doppler effect. The Doppler frequency is within the
audible range. Mathematically, this can be represented: Fd = fe – fo, where Fd is the
Doppler shift, fe is the echo (reflected wave) and fo is the incident wave (with a known
frequency). According to the Doppler equation for a reflector, the velocity of the moving
target can be calculated with the equation:
v =         c * fo         .
2 * fo* cos Θ
where v is the velocity of the moving target, and c is the speed of the incident wave. The
target moves in the direction of the probe at an angle of Θ, the Doppler angle.
In 1982, the first transcranial Doppler (TCD) was introduced and allowed non-invasive
assessment of intracranial hemodynamics.114 The low-frequency (2-4 Mhz) Doppler
probe measures blood flow velocity in cerebral arteries through the thinnest portions of
the intact skull.115 The TCD signal is displayed as a velocity-time waveform. The peak
systolic (PSV) and end-diastolic (EDV) blood flow velocities can be ascertained directly
from the TCD waveform.116 The mean blood flow velocity (MV) can be calculated:
MV = PSV + (EDV * 2)
3
According to the Hagen-Poiseuille law, flow in a rigid tube is:
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F = P * π * r4
     8 * η * l
where F is flow, r is the radius of the tube, l is the length of the tube, P is the change in
the pressure over the length of the tube, and η is the viscosity of the fluid.
The relationship between flow and velocity through a tube is defined:
F = v * π * r2
Combining the previous formula for flow with the Hagen-Poiseuille law117:
v =     P * r2     .
    8 * η * l
TCD is used for interrogation of the cerebral circulation through four “windows” in the
intact skull.114 The four windows are in the temporal, orbital, submandibular, and
suboccipital areas.114 The temporal window is used to measure blood velocity in middle
cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA)
and communicating arteries (Figure 5).114 The transorbital approach allows assessment of
blood velocity in the ophthalmic artery (OA) and internal carotid artery (ICA) siphon.114
The submandibular window is used to measure blood velocity in the ICA as it enters the
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skull.114 The suboccipital approach allows assessment of blood velocity in the terminal
vertebral arteries (VA) and basilar artery (BA) through the foramen magnum.114
Figure 5. Schematic drawing of insonation through the temporal window using transcranial Doppler.
Transcranial Doppler measures the cerebral blood flow velocity in the cerebral arteries. The transtemporal
approach allows for measurement of the (1) posterior (2) middle and (3) anterior cerebral arteries. (From
Franco Folino, 2007)
In 1982, Aaslid determined a range of normal blood flow velocities and depths of
insonation for each of the major intracranial arteries116, 118. The blood flow velocity
depends on the angle of insonation, vessel diameter, cerebral blood flow and collateral
flow.116 The range that was established for MCA blood flow velocity was 46-86 cm/s,
toward the ultrasound probe through the temporal window, at a depth of 35-60 mm.116, 118
The mean velocity obtained in the MCA by Aaslid et al. in 1982 was 62 +/- 12 cm/s.118
Cerebral blood flow is dependent on the radius of the vessel and the blood flow velocity
through the vessel.117 The blood flow velocity is dependent on the perfusion pressure
across the vessel, the radius of the vessel and the hematocrit of the blood.117 Physiological
factors that influence blood flow velocity are similar to those that change cerebral blood
flow: mean arterial pressure, partial pressure of CO2, and hematocrit.116
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The TCD waveform is determined by a number of factors including cardiac output and
blood pressure, as well as autoregulatory or vasomotor responses and focal arterial
lesions within the brain.114 Hypertension (both chronic and acute) increases blood flow
pulsatility and may increase the mean flow velocity.114 Hyperventilation decreases the
mean flow velocity and increases the pulsatility of flow.114 Hypercapnia increases the
mean flow velocity and decreases pulsatility of flow.114 A waveform pattern can also be
affected by downstream circulatory conditions, such as loss of autoregulation or elevated
intracranial pressure.114 When homologous arterial segments are compared, normal
variations of up to 30% in flow velocities and pulsatility indices can be expected.114
Variations in the angle of insonation can account for 15% of a normal velocity/pulsatility
difference and the resistance of downstream vasculature during breathing cycles for
another 15%.114
The importance of assessing cerebral blood flow as indicated by cerebral blood flow
velocity is based on the knowledge that cerebral blood circulation appears to directly
influence cerebral function.119 Cerebral blood flow and mean flow velocities decrease
with age in adults.117 TCD is used to evaluate traumatic brain injuries, acute and chronic
cerbrovascular disease, and unexplained syncope.19 Cerebral blood flow monitoring with
TCD during circulatory arrest and cardiopulmonary bypass116 leads to improved
neurological outcomes in neonates and children undergoing congenital heart repair.117
TCD has been useful for detecting emboli,116, 117 improper cannulation or cross clamping
of aortic arch vessels during cardiac surgery.117 TCD is utilized for the clinical evaluation
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of cerebral vasospasm following subarachnoid hemorrhage and monitoring of cerebral
hemodynamics following head trauma.116 Less frequently, TCD is used to diagnose brain
death.116
Transcranial Doppler is the most popular way to assess cerebral autoregulation;115, 116 it
can be used to measure both dynamic and static autoregulation.19 Specifically, it provides
real-time information about changes in cerebral blood flow velocity and allows for the
study of dynamic autoregulation.19 An index of autoregulation can be calculated as a
percentage change in cerebrovascular resistance (MAP/CBFV) per 1% change in MAP
(CBFV is measured using transcranial Doppler).116 A value lower than 0.4 indicates
impaired autoregulation.116 Using spectral-domain analysis, one can determine the
contribution of parasympathetic, sympathetic and other influences on the regulation of
the middle cerebral artery.
Calculation of the Pulsatility Index (PI) and Resistance Index (RI) from the measured
blood flow velocities gives information about the resistance of more distal vasculature
(PI) and increased intracranial pressure (PI and RI).116
PI = PSV – EDV
       MV
RI = PSV – EDV
        PSV
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PSV is peak systolic blood flow velocity, EDV is end diastolic blood flow velocity, and
MV is mean velocity (calculation of MV shown above).
Using TCD to evaluate absolute blood flow is not possible because the precise diameter
of the blood vessel is not known.117 Changes in cerebral blood flow can, however, can be
accurately estimated by the change in cerebral blood flow velocity measured by TCD in
the MCA.117 The caveat to the relationship is that the CBF and cerebral blood flow
velocities are correlated in a linear fashion only if the angle of insonation and vessel
caliber remains constant throughout the exam.116 There are some studies that suggest that
the diameter of the MCA does not change significantly during cardiovascular challenges
such as pediatric cardiac surgery, with the vascular changes occurring only in resistance
arteries and arterioles.117, 120
Use of TCD is limited by multiple factors. It is operator dependent,19 with a steep
learning curve before technical proficiency is gained. It can only measure velocity in
large arteries.115 Regional cerebral autoregulation defects could be missed because of
averaging with areas that have better perfusion.115 Collateral circulation can weaken the
correlation between cerebral blood flow velocities and cerebral blood flow.121 Significant
moment to moment variation means that intermittent TCD could miss important peaks or
troughs in blood flow velocities.116 Up to 8% of subjects do not have an adequate acoustic
window for insonation.116, 122
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Research Applications for TCD:
Using TCD during experimental models of hypoperfusion is convenient because it
provides a non-invasive, objective measure of the amount of blood perfusing the brain.117
The mean cerebral blood flow velocity (CBFV) seems to be the most important value for
describing cerebral perfusion, rather than systolic cerebral blood flow velocity.7, 117
During one study by Balldin et al., with maximal LBNP prior to syncope, a decline in
mean CBFV of 60% from baseline was been noted.7 This diminished flow velocity
continues at the third heartbeat after the release of LBNP, but begins to recover by 30
seconds after release (84% of baseline).7 Mean CBFV is not completely restored to
baseline levels up to 30 seconds after the release of LBNP.7
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Specific Aims of the Present Study
The present study was undertaken to determine if the Cholinergic Oscillatory Control of
the microvasculature (COCVASC)3 is present in the setting of hypoperfusion, as it was in
the setting of vasoconstrictive challenges.2-5 The change in blood flow at the level of the
microcirculation is compared to the change in blood flow velocity in the middle cerebral
artery to determine if either monitor better predicts symptom onset during hypoperfusion.
An evaluation of the power in the autonomic spectra of the signals generated by the TCD
and the forehead LD allows for the quantification of the relative contributions of the
sympathetic and parasympathetic nervous systems.
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Methods
With Institutional Review Board approval, 11 healthy non-smoking volunteers were
given informed consent in the protocols and procedures involved in the experiment.
Subjects were instructed to refrain from caffeine and other known vasoactive compounds
for at least 8 h and to eat only a light meal prior to their scheduled experiment time.
Instrumentation:
Subjects were positioned within the LBNP chamber such that their anterior superior iliac
crests were aligned with the opening and then a piece of wood with a cutout for their
abdomen was placed at the edge of the chamber. The kayak skirt was stretched over the
lip of the chamber entrance and the top of the skirt was secured tightly with a Velcro
strap. A leg roll was placed under the knees and a footrest was positioned at the end of
the chamber. The climbing harness was connected to eye-loops in the chamber via nylon
rope and the subject was fastened into place. The Plexiglas lid was then closed and
locked. The negative pressure is turned on and can be adjusted using a manual dial. A
manometer is present to monitor the pressure inside of the chamber.
Protocol:
Subjects were placed in the recumbent position on a table with their legs and pelvis inside
of a horizontal, wooden lower body negative pressure chamber, in a temperature-
regulated room (25°C). They were fitted with a mountain-climbing harness and kayak
skirt prior to lying down. Surface electrodes were applied for monitoring the
40
electrocardiogram (ECG), a respiration belt was placed around the thorax, and a
noninvasive blood pressure cuff was placed on one arm. Blood pressure, mean arterial
pressure and stroke volume were registered by a noninvasive pneumatic finger cuff
(Finapres, Ohmeda model 2300, Madison, WI). Laser Doppler flowmetry probes
(Periflux 2B; Perimed, Sweden) were applied to the skin via double-stick tape on the
forehead and on the ventral finger, contralateral to the arm blood pressure cuff. A
transcranial Doppler transducer in a manually adjustable headset was positioned over the
temporal acoustic window until a mean blood flow velocity of at least 50 cm/s was
obtained. The depth and gain was adjusted to optimize the signal for each subject.
Data Collection:
The ECG, respiration, blood pressure, stroke volume, TCD blood flow velocity and laser
Doppler flux were recorded through a PowerLab data acquisition unit, at 250 Hz, with
commercially available data acquisition software (LabChart software; ADInstruments).
For forehead LD, TCD, and Finapres arterial blood pressure, systolic (peak) and diastolic
(trough) values were recorded. Data from Chart was analyzed using peak analysis and the
average, minimum and maximum values during specific 30-second intervals were
transferred to Microsoft Excel. In Microsoft Excel, mean and standard deviation
calculations, and two-tailed paired t-tests were performed on each interval. These
intervals were labeled “Baseline,” “Presympt,” “Sympt” and “Recovery.”
There was a baseline period of data collection that lasted approximately 3 minutes in each
subject, during which LBNP was not applied to the subject. The “Baseline” interval used
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in data analysis was described as a 30-second interval during the baseline period of data
collection. The volunteers were subjected to a rapidly progressive LBNP protocol (-70
mmHg in 1 min followed by progressive declines of ~10 mmHg until they reported
lightheadedness or had a BP decline >20% baseline BP). Presympt is the pre-
symptomatic period. All subjects have a Presympt period at approximately 30 seconds
before Sympt, even if they did not become symptomatic. Presympt is a marker of the
time of the maximum LBNP and occurs just prior to discontinuation of LBNP. Sympt is a
30-second interval that begins with the subject reporting symptoms of nausea or
lightheadedness. However, subjects who did not report symptoms during LBNP still have
a Sympt period, which is the time of discontinuation of LBNP for safety reasons. LBNP
was discontinued for safety if a subject had a decline in SBP >20% baseline BP or a
doubling of their heart rate. LBNP was also discontinued for discomfort in one subject
who had groin pain.
Data Analysis:
Customized modifications of the spectral-domain analysis program in commercially
available software (Chart; Igor Pro, Wavemetrics, Inc., Lake Oswego, OR) were used to
enable analysis of continuous flow. The frequency and power of the oscillatory activity of
the R-R tachogram, transcranial Doppler flow velocity, and laser Doppler flux signals
were characterized with the autopower spectral density (APSD):
Gaa = [ave(Sa Sa* )]/df,
42
wherein Gaa is the instantaneous amplitude spectral density of channel “a” [e.g., R-R
intervals (in msec) or forehead flow (in volts) or transcranial Doppler flow velocity (in
cm/s)], Sa is instantaneous amplitude spectrum of channel “a”, Sa* is complex conjugate
of Sa, and df is frequency resolution [0.01 Hz for a 40 sec window (e.g., APSD0-40 )].
These were displayed with frequency (from 0.05 – 0.30 Hz) on the x-axis and power for
each frequency (in msec2 /Hz or volt2 /Hz or (cm/s) 2/Hz) on the y-axis. Joint time-
frequency analysis (JTFA) was performed on the “moving,” overlapping windows. After
the APSD0-40 window was generated, subsequent windows were automatically shifted
every 20 sec, such that each successive window incorporated the next 20 sec block of
data and excluded the prior window’s earliest 20 sec block of data (20-60 sec, 40-80 sec
…). The data for the successive windows were converted to a spreadsheet (Excel,
Microsoft, Redmond, WA) with successive 0.025 Hz frequency bins in each column and
successive 20 sec increments of the APSD40 in each row. Initially, APSD40 were
generated for the entire TCD and the continuous forehead flow waveform. These were
converted to the aforementioned spreadsheet with successive 0.025 Hz frequency bins in
each column. The eleven 0.025 Hz-wide bins between 0.05 and 0.30 Hz were grouped
into the following frequency bands: low (0.05-0.11 Hz), intermediate (0.12-0.18 Hz),
respiratory (0.19-0.21 Hz) and remainder of the high (0.21-0.30).
Finally, the results of spectral-domain analysis for each individual was correlated to the
timing in Chart and labeled with “Baseline,” “Presympt,” “Sympt,” and “Recovery”
intervals. The entire baseline period of the study was averaged for each spectral-domain
frequency interval (e.g. 0.05, 0.075, 0.1, etc.) for each individual. In order to show a
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difference from baseline, the 85th percentile of baseline was calculated and was then
compared to the “Presympt,” “Sympt,” and “Recovery” 30-second intervals. The absolute
difference of the Presympt, Sympt or Recovery value minus the upper limit of the 85th
percentile of the baseline interval was then divided by the average of the baseline and
multiplied by 100 to give percent change from baseline. If the Presympt, Sympt or
Recovery value was lower than the 85th percentile baseline range, then the Presympt,
Sympt or Recovery value was subtracted from the minimum value of the baseline range
and divided by the average of the baseline and multiplied by –100 to give percent change
from baseline (with a negative value indicating that it is below the baseline range).
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Results
Of the eleven healthy volunteers enrolled in the study, two were excluded based on poor
quality of data collection. Nine subjects were able to tolerate the lower body negative
pressure challenge. Seven of the nine subjects became symptomatic – six with
lightheadedness, plus or minus nausea, and one subject with nausea only. Two subjects
did not become symptomatic with progressive LBNP – one subject had significant groin
pain and the study was terminated because of pain, and one subject had no symptoms
until after the LBNP was discontinued, at which point he experienced nausea. Subjects
have been grouped, therefore, into the following categories: All (all nine subjects);
symptomatic (seven symptomatic); lightheaded (six symptomatic subjects with
lightheadedness); nauseous (two subjects with nausea – one during LBNP and one
immediately after its discontinuation); asymptomatic (two subjects who did not have
symptoms prior to discontinuation of LBNP). Maximum LBNP tolerated by each subject
group is listed in Table A. The average of maximum LBNP tolerated did not vary
significantly between symptomatic and asymptomatic subject groups, though there was a
trend toward further progression of LBNP in asymptomatic subjects (-110 mmHg in
asymptomatic vs. –94.3 mmHg in symptomatic subjects, p= NS)
Subject Group (Individual Subjects) Maximum LBNP
All Subjects (A-I) -97.8 mmHg
Symptomatic (A-G) -94.3 mmHg
Lightheaded (B-G) -95 mmHg
Nauseous (A, I) -97.5 mmHg
Asymptomatic (H, I) -110 mmHg
Table A.  Maximum Lower Body Negative Pressure (LBNP) tolerated in each subject group
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Blood Pressure:
Lower body negative pressure induced predictable changes in systemic blood pressure
and heart rate (See Tables B and C; Figures 1 and 2).
Average Systemic Pressure Baseline Presympt Sympt Recovery
All:
Systolic 126.211 115.14* 101.73* 119.644
Diastolic 72.464 80.96* 72.342 76.451
Pulse Pressure 53.738 34.20* 29.40* 43.20*
 
Symptomatic:
Systolic 128.200 117.41* 105.58* 120.457
Diastolic 72.261 81.73* 72.886 76.491
Pulse Pressure 55.930 35.70* 32.71* 43.97*
 
Lightheaded:
Systolic 131.800 119.22* 103.50* 120.47*
Diastolic 75.420 83.49* 72.248 78.533
Pulse Pressure 56.375 35.74* 31.26* 41.95*
 
Nauseous:
Systolic 110.950 104.800 99.785 117.350
Diastolic 63.155 73.130 70.575 68.020
Pulse Pressure 47.770 31.690 29.205 49.315
 
Asymptomatic:
Systolic 119.250 107.2* 88.265 116.800
Diastolic 73.175 78.275 70.440 76.310
Pulse Pressure^ 46.065 28.950 17.820 40.475
Table B. Average Systemic Blood Pressure. The average systolic blood pressure (SBP), diastolic blood
pressure (DBP), and pulse pressure for each subject group are shown, during Baseline, Presympt, Sympt
and Recovery. Significant changes from Baseline are represented with “*” and signify p<0.05. Significant
changes between Presympt and Sympt are represented with “^” and signify p<0.05.
Table C. Average Heart Rate (HR). The average heart rate during Baseline, Presympt, Sympt and
Recovery for each subject group is shown. Significant changes from Baseline are represented with “*” and
signify p<0.05. There were no significant changes between Presympt and Sympt in any subject group.
Heart Rate        
  Baseline Presympt Sympt Recovery
All Subjects 67.9 108.7* 101.2* 59.6*
Symptomatic 64.8 104.3* 101.4* 57.7*
Lightheaded 66 103.3* 99.7* 57.2*
Nauseous 72.5 113.1 112.4 67.4
Asymptomatic 78.8 124.2 100.7 66.3*
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In all subjects, the average systolic blood pressure (SBP) declined from Baseline at 126.2
mmHg to Presympt at 115.1 mmHg (p<0.001) and to Sympt at 101.7 mmHg (p = 0.008);
diastolic blood pressure (DBP) increased significantly from Baseline at 72.5 mmHg to
Presympt at 81.0 mmHg (p = 0.005); pulse pressure declined from Baseline at 53.7
mmHg to Presympt at 34.2 mmHg (p<0.001) and to Sympt at 29.4 mmHg (p<0.001) and
to Recovery at 43.2 mmHg (p = 0.017). There were no significant changes in SBP, DBP
or pulse pressure between Presympt and Sympt (p = NS). In symptomatic subjects,
average SBP declined from Baseline at 128.2 mmHg to Presympt at 117.4 mmHg (p =
0.003) and to Sympt at 105.6 mmHg (p = 0.044); DBP increased significantly from
Baseline at 72.2 mmHg to Presympt at 81.7 mmHg (p = 0.012); pulse pressure declined
from Baseline at 55.9 mmHg to Presympt at 35.7 mmHg (p<0.001) and to Sympt at 32.7
mmHg (p = 0.002) and to Recovery at 44.0 mmHg (p = 0.030). There were no significant
changes in SBP, DBP or pulse pressure between Presympt and Sympt (p = NS). In
lightheaded subjects, average SBP declined from Baseline at 131.8 mmHg to Presympt at
119.2 mmHg (p<0.001) and to Sympt at 103.5 mmHg (p = 0.017) and to Recovery at
120.5 (p = 0.045); DBP increased significantly from Baseline at 75.4 mmHg to Presympt
at 83.5 mmHg (p = 0.030); pulse pressure declined from Baseline at 56.4 mmHg to
Presympt at 35.7 mmHg (p<0.001) and to Sympt at 31.3 mmHg (p = 0.003) and to
Recovery at 42.0 mmHg (p = 0.017). There were no significant changes in SBP, DBP or
pulse pressure between Presympt and Sympt (p = NS). In nauseous subjects, average
SBP, DBP and pulse pressure did not change significantly between any of the analyzed
stages. In asymptomatic subjects, average SBP declined from Baseline at 119.3 mmHg to
Presympt at 107.2 mmHg (p = 0.013), however there were no other significant changes in
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SBP, DBP. Pulse pressure changed significantly from Presympt at 29.0 mmHg to Sympt
at 17.8 mmHg (p = 0.011). (See Table B)
Heart Rate:
In all subjects, the heart rate (HR) increased from Baseline at 67.9 bpm to Presympt at
108.7 (p = 0.0008 for interphase difference by two-tailed paired t-test) and from Baseline
to Sympt at 101.2 bpm (p = 0.003) and HR declined from Baseline to Recovery at 59.6
bpm (p = 0.0022). In symptomatic subjects, HR increased from Baseline at 64.8 bpm to
Presympt at 104.3 (p = 0.006) and to Sympt at 101.4 bpm (p = 0.010); HR declined from
Baseline to Recovery at 57.7 bpm (p = 0.019). In lightheaded subjects, HR increased
from Baseline at 66 bpm to Presympt 103.3 bpm (p = 0.019) and to Sympt at 99.7 bpm (p
= 0.031); HR declined from Baseline to Recovery at 57.2 (p = 0.005). There was no
significant change in HR in nauseous subjects (p = NS). In asymptomatic subjects, the
only significant change in HR was between Baseline at 78.8 bpm and Recovery at 66.3
bpm (p = 0.012). There was no difference in HR between Presympt and Sympt (p = NS)
in any group. (See Table C)
Forehead Laser Doppler Flow:
Forehead LD Flow changed significantly only from BaselineSYS to SymptSYS (*p=0.048)
in all subjects. In symptomatic subjects, the average Forehead LD Flow changed
significantly only from PresymptSYS to SymptSYS (p=0.040). In lightheaded subjects, the
Forehead LD Flow changed significantly only from Presympt SYS to Sympt SYS (p=0.040).
In nauseous subjects, the Forehead LD Flow changed significantly only from
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BaselineHEIGHT to PresymptHEIGHT (0.004). In asymptomatic subjects, the Forehead LD
Flow did not change significantly between any measured intervals. Any p-value not
shown is p= not significant (NS). (See Figures 1 and 2)
Transcranial Doppler Flow:
Transcranial Doppler Flow Velocity changed significantly in all subjects from
BaselineSYS to PresymptSYS (*p<0.001), BaselineSYS to SymptSYS (*p<0.001), BaselineDIAS
to PresymptDIAS (*p=0.018), BaselineDIAS to SymptDIAS (*p=0.003), PresymptDIAS to
SymptDIAS (^p=0.012), BaselineHEIGHT to PresymptHEIGHT (p<0.001) BaselineHEIGHT to
SymptHEIGHT (p=0.008). In symptomatic subjects, the TCD Flow Velocity changed
significantly from Baseline SYS to Presympt SYS (p<0.001), Baseline SYS to Sympt SYS
(p=0.002), BaselineDIAS to PresymptDIAS (p=0.022), BaselineDIAS to SymptDIAS (p=0.014),
PresymptDIAS to SymptDIAS (p=0.045), and BaselineHEIGHT to PresymptHEIGHT (p<0.001). In
lightheaded subjects, the TCD Flow Velocity changed significantly from Baseline SYS to
Presympt SYS (p=0.001), Baseline SYS to Sympt SYS (p=0.005), BaselineDIAS to PresymptDIAS
(p=0.026), BaselineDIAS to SymptDIAS (p=0.009), PresymptDIAS to SymptDIAS (p=0.016), and
BaselineHEIGHT to PresymptHEIGHT (p=0.001). In nauseous subjects, TCD Flow Velocity
changed only significantly from BaselineHEIGHT to SymptHEIGHT (p=0.021). In
asymptomatic subjects, the TCD Flow Velocity changed significantly from Baseline SYS
to RecoverySYS (p=0.047), BaselineHEIGHT to PresymptHEIGHT (p=0.014), BaselineHEIGHT to
SymptHEIGHT (p=0.022). Any p-value not shown is p = NS. (See Figures 6 and 7)
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Figure 6. Comparison of Average Forehead Laser Doppler Flow to Transcranial Doppler Flow Velocity.
The average Forehead LD Flow and TCD Flow Velocity during Baseline, Presympt, Sympt and Recovery
are shown for each group of subjects. Significant changes from Baseline are represented with “*” and
signify p<0.05. Significant changes between Presympt and Sympt are represented with “^” and signify
p<0.05.
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Figure 7. Systemic Blood Pressure, Forehead Laser Doppler Flow and Transcranial Doppler Flow
Velocity. Individual patterns of systemic blood pressure, forehead LD and TCD are represented in the
above graphs. Subjects A-G are symptomatic; Subject A became nauseous with LBNP and Subjects B-G
became lightheaded and nauseous. Subject H was asymptomatic, but had groin pain at the end of the study.
Subject I was asymptomatic and became nauseous after the LBNP was discontinued. Systolic: Peak value;
Diastolic: Trough value; Pulse Pressure or Height: numerical difference between peak and trough.
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Figure 7 (cont). Systemic Blood Pressure, Forehead Laser Doppler Flow and Transcranial Doppler Flow
Velocity. Individual patterns of systemic blood pressure, forehead LD and TCD are represented in the
above graphs. Subjects A-G are symptomatic; Subject A became nauseous with LBNP and Subjects B-G
became lightheaded and nauseous. Subject H was asymptomatic, but had groin pain at the end of the study.
Subject I was asymptomatic and became nauseous after the LBNP was discontinued. Systolic: Peak value;
Diastolic: Trough value; Pulse Pressure or Height: numerical difference between peak and trough.
Autonomic Power:
The overall changes in autonomics were analyzed via spectral-domain analysis of the
Heart Rate Variability (HRV), Transcranial Doppler (TCD) Flow Velocity and Forehead
Laser Doppler (LD) Flux. HRV varied significantly between Presympt and Sympt in the
asymptomatic subjects (p = 0.021), but did not have a significant change in other subject
groups during the course of progressive LBNP. (See Table D)
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HRV: LF/HF        
  Baseline Presympt Sympt Recovery
All 2.77 27.65 14.12 2.90
Symptomatic 3.06 35.04 16.51 3.08
Lightheaded 2.69 38.40 17.86 2.64
Nauseous 2.76 8.56 7.24 3.61
Asymptomatic^ 1.77 1.79 5.78 2.28
Table D. Heart Rate Variability (HRV). The average HRV during Baseline, Presympt, Sympt and
Recovery is shown for each subject group. Significant changes between Presympt and Sympt are
represented with “^” and signify p<0.05. There were no significant changes in HRV between Baseline and
Presympt, Sympt or Recovery.
Changes in the autonomic power in the Forehead LD Flow and TCD Flow Velocity for
each subject group are listed below. The data represents a percentage change from a
“baseline range.” The baseline range includes approximately 85% of numerical values
you would expect to find during baseline. If a percentage change is equal to 200%, this
indicates that the power at this frequency is 200% (or twice the power) of the maximum
baseline range value. If the percentage is negative, this indicates that the change in power
is below the minimum number in the baseline range. (See Figure 8; See Tables E-I and J-
N)
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All
Subjects
Forehead LD
% Change from Baseline
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0
Presympt 6.8 131.5 154.6 182.1 262.6 203.5 243.0 270.8 286.7
Sympt 48.8 313.7 529.9 446.5 310.5 600.0 262.8 578.2 306.5
Recovery 2.2 -4.3 -11.6 -5.7 23.7 19.6 0.8 101.7 433.3
Table E. Percent change in Forehead LD flow in All Subjects. Numbers listed represent the difference
between the maximum power in the baseline range (approximately the 85th percentile) and the power at
each frequency during the specified interval, divided by the average of baseline and multiplied by 100%. If
a number is negative, the power at that frequency was subtracted from the minimum power in the baseline
range and was then divided by the average of baseline and multiplied by –100%. Negative numbers
therefore represent a change that is below what would be expected at baseline.
Symptomatic
Subjects      
Forehead LD
% Change from Baseline          
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0
Presympt -1.3 29.3 95.7 210.7 271.0 261.6 311.9 333.9 299.2
Sympt 5.6 33.2 -4.4 -12.2 299.3 719.2 48.4 419.1 309.9
Recovery 4.1 -3.6 -6.8 -7.4 31.2 30.1 10.5 130.7 557.1
Table F. Percent change in Forehead LD flow in Symptomatic Subjects. Numbers listed represent the
difference between the maximum power in the baseline range (approximately the 85th percentile) and the
power at each frequency during the specified interval, divided by the average of baseline and multiplied by
100%. If a number is negative, the power at that frequency was subtracted from the minimum power in the
baseline range and was then divided by the average of baseline and multiplied by –100%. Negative
numbers therefore represent a change that is below what would be expected at baseline.
Lightheaded
Subjects
Forehead LD
% Change from Baseline
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0
Presympt -1.6 34.2 70.7 44.2 75.7 116.1 321.3 389.6 231.6
Sympt -0.2 38.8 -6.1 -14.2 127.5 18.5 53.9 443.7 349.6
Recovery 7.0 -1.4 -7.7 -8.6 33.7 9.8 10.8 152.5 653.9
Table G. Percent change in Forehead LD flow in Lightheaded Subjects. Numbers listed represent the
difference between the maximum power in the baseline range (approximately the 85th percentile) and the
power at each frequency during the specified interval, divided by the average of baseline and multiplied by
100%. If a number is negative, the power at that frequency was subtracted from the minimum power in the
baseline range and was then divided by the average of baseline and multiplied by –100%. Negative
numbers therefore represent a change that is below what would be expected at baseline.
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Nauseous
Subjects
Forehead LD
% Change from Baseline
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Presympt 46.5 150.9 128.5 684.6 846.3 567.4 138.3 10.4 341.2
Sympt 220.0 1248.6 2360.6 2052.2 1031.2 2661.5 1021.0 1184.3 208.9
Recovery -11.2 -15.2 -29.1 0.0 8.0 75.8 -6.5 0.0 -12.1
Table H. Percent change in Forehead LD flow in Nauseous Subjects. Numbers listed represent the
difference between the maximum power in the baseline range (approximately the 85th percentile) and the
power at each frequency during the specified interval, divided by the average of baseline and multiplied by
100%. If a number is negative, the power at that frequency was subtracted from the minimum power in the
baseline range and was then divided by the average of baseline and multiplied by –100%. Negative
numbers therefore represent a change that is below what would be expected at baseline.
Asymptomatic
Subjects
Forehead LD
% Change from Baseline
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Presympt 35.1 489.2 360.4 82.0 233.2 0.0 1.9 49.8 242.9
Sympt 199.8 1295.3 2400.1 2052.2 349.7 182.8 1013.1 1135.0 294.9
Recovery -4.4 -6.8 -28.4 0.0 -2.4 -17.0 -32.9 0.0 0.0
Table I. Percent change in Forehead LD flow in Asymptomatic Subjects. Numbers listed represent the
difference between the maximum power in the baseline range (approximately the 85th percentile) and the
power at each frequency during the specified interval, divided by the average of baseline and multiplied by
100%. If a number is negative, the power at that frequency was subtracted from the minimum power in the
baseline range and was then divided by the average of baseline and multiplied by –100%. Negative
numbers therefore represent a change that is below what would be expected at baseline.
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All
Subjects
TCD
% Change from Baseline      
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 0.9 0.0 0.0 3.1 0.0 0.0
Presympt 68.6 70.8 216.6 101.2 56.2 77.3 189.6 172.9 249.4
Sympt 27.2 59.5 255.6 457.8 201.0 308.8 435.2 168.6 340.4
Recovery -6.6 23.1 45.8 67.3 69.4 87.0 119.5 49.2 25.1
Table J. Percent change in TCD Flow Velocity in All Subjects. Numbers listed represent the difference
between the maximum power in the baseline range (approximately the 85th percentile) and the power at
each frequency during the specified interval, divided by the average of baseline and multiplied by 100%. If
a number is negative, the power at that frequency was subtracted from the minimum power in the baseline
range and was then divided by the average of baseline and multiplied by –100%. Negative numbers
therefore represent a change that is below what would be expected at baseline.
Symptomatic
Subjects
TCD
% Change from Baseline      
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0
Presympt 83.1 31.6 171.6 120.2 50.2 78.8 241.8 217.5 320.6
Sympt 37.8 76.5 143.6 258.6 93.1 397.0 413.9 153.9 134.6
Recovery -12.5 34.1 64.4 88.6 92.1 111.9 124.3 63.2 34.4
Table K. Percent change in TCD Flow Velocity in Symptomatic Subjects. Numbers listed represent the
difference between the maximum power in the baseline range (approximately the 85th percentile) and the
power at each frequency during the specified interval, divided by the average of baseline and multiplied by
100%. If a number is negative, the power at that frequency was subtracted from the minimum power in the
baseline range and was then divided by the average of baseline and multiplied by –100%. Negative
numbers therefore represent a change that is below what would be expected at baseline.
Lightheaded
Subjects
TCD
% Change from Baseline    
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0
Presympt 97.0 17.6 70.9 93.5 25.6 2.3 268.9 238.7 314.4
Sympt -3.4 89.3 167.6 301.6 2.3 440.7 482.9 168.8 145.7
Recovery -14.5 43.8 75.2 103.4 107.5 130.6 146.6 73.8 40.1
Table L. Percent change in TCD Flow Velocity in Lightheaded Subjects. Numbers listed represent the
difference between the maximum power in the baseline range (approximately the 85th percentile) and the
power at each frequency during the specified interval, divided by the average of baseline and multiplied by
100%. If a number is negative, the power at that frequency was subtracted from the minimum power in the
baseline range and was then divided by the average of baseline and multiplied by –100%. Negative
numbers therefore represent a change that is below what would be expected at baseline
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Nauseous
Subjects
 TCD
% Change from Baseline      
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.00 0.00 0.00 0.00 0.00 0.00 14.0 0.00 0.00
Presympt 26.2 265.6 771.3 174.6 176.3 324.0 46.4 63.8 178.9
Sympt 142.5 0.00 648.9 1159.4 897.4 67.3 509.6 32.5 894.1
Recovery -2.8 -27.6 -5.7 0.00 -10.00 0.00 97.7 0.00 -7.6
Table M. Percent change in TCD Flow Velocity in Nauseous Subjects. Numbers listed represent the
difference between the maximum power in the baseline range (approximately the 85th percentile) and the
power at each frequency during the specified interval, divided by the average of baseline and multiplied by
100%. If a number is negative, the power at that frequency was subtracted from the minimum power in the
baseline range and was then divided by the average of baseline and multiplied by –100%. Negative
numbers therefore represent a change that is below what would be expected at baseline.
Asymptomatic
Subjects
TCD
% Change from Baseline
  0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 0.250
Baseline 0.0 0.0 0.0 0.0 0.0 0.0 14.0 0.0 0.0
Presympt 17.5 207.9 374.0 34.5 77.3 72.0 6.7 16.7 0.0
Sympt -9.6 0.0 647.4 1155.0 578.6 0.0 509.6 219.8 1060.7
Recovery 14.0 -15.7 -19.6 -7.1 -10.0 0.0 102.4 0.0 -7.6
Table N. Percent change in TCD Flow Velocity in Asymptomatic Subjects. Numbers listed represent the
difference between the maximum power in the baseline range (approximately the 85th percentile) and the
power at each frequency during the specified interval, divided by the average of baseline and multiplied by
100%. If a number is negative, the power at that frequency was subtracted from the minimum power in the
baseline range and was then divided by the average of baseline and multiplied by –100%. Negative
numbers therefore represent a change that is below what would be expected at baseline.
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Figure 8. Comparison of Forehead LD Change in Power from Baseline and TCD Percent Change from
Baseline. Graphical representation of the average percent change in power from Baseline at each frequency
in the different subject groups.
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Discussion
Rapid ramping of LBNP successfully simulated acute central hypovolemia during the
present research protocol. Progressive LBNP resulted in strong evidence of systemic
sympathetic compensation, including tachycardia, decreased heart rate variability,
decreased flow measurements in the extremities (finger laser Doppler flow declined
during progressive LBNP, data not shown), decreased stroke volume (data not shown)
and decreased arterial pulse pressure. Of the nine subjects who tolerated LBNP, six
became lightheaded, one became nauseous only, and two did not develop symptoms
during the progression of LBNP. Upon analysis of the data and consideration of subject
symptom characteristics, a decision was made to divide lightheaded subjects from
nauseous subjects, because lightheadedness is a clear indicator of decreased cerebral
perfusion, whereas nausea may be a vagal response or could be mediated by some other
process unrelated to cerebral perfusion.
In the 6 subjects who became lightheaded, forehead LD decreased by 10.9±11.7% from
Baseline at Presympt (p=NS for interphase difference). It then decreased by an additional
20.4±18.7% with the onset of lightheadedness (p=0.035 for Presympt vs. Sympt).
Forehead LD flow was predictive of symptom onset. Forehead LD changed significantly
in a manner that predicted the occurrence of lightheadedness in a subject. The forehead
LD peak (systole) and trough (diastole) values did not change during the course of LBNP
in the nauseous or asymptomatic groups (where Sympt was the time when the study was
terminated because the BP cutoff was reached). In the symptomatic and lightheaded
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groups, the only significant change in Forehead LD was between PresymptSYS and
SymptSYS.
TCD flow velocity changed frequently throughout the progression of LBNP. Peak TCD
readings in lightheaded subjects decreased by 29.3±9.7% from Baseline to the time of the
Presympt measurement (p=0.001); they then increased by 4.1±12.9% with the onset of
Sympt (p=NS). (The relatively high standard deviations reflect inter-subject, not intra-
subject, variability.) There was no significant change in the TCD flow velocity in the
nauseous or asymptomatic subjects, but the downward trends may have reached
significance if there were enough subjects in those groups.
The specificity of the forehead LD is ideal as a predictor of impending circulatory
collapse. Forehead LD flow could be a surrogate for microvasculature in the brain
because the vascular supply is the same (the internal and external carotid arteries) and
because the forehead microvascular flow is spared during vasoconstriction and
hypovolemia until symptoms occur.
TCD, however, may not consistently predict symptoms in the context of acute
hypovolemia. The lack of a continued decline in TCD velocity might be attributed to a
stabilization of stroke volume; however, the data suggest that stroke volume continues to
decline at the levels of LBNP used in the present study.89 Vasoconstriction at the site of
TCD measurement would increase velocity within the vessel segment; however, this
would not account for divergent responses during systole and diastole. When the TCD
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trend follows systemic MAP, cerebral autoregulation has been compromised. However,
when systemic MAP continues to fall, but TCD levels off, this is evidence of dynamic
cerebral autoregulation (an effort to maintain perfusion of the brain in the setting of
decreased cardiac output). In the symptomatic and lightheaded groups, the TCD diastolic
value continues to fall between Presympt and Sympt – along with MAP – which is an
indication that the subjects have lost the ability to protect the brain’s blood supply.
The discordance between LD and TCD may be consistent with autoregulatory
mechanisms at the level of the forehead microvasculature that have been reported in the
context of systemic administration of phenylephrine.3, 4 Subjects in the phenylephrine
studies were not pushed to the point of symptoms and the cerebral blood flow was not
monitored, therefore our data gives more global information about the subjects and their
ability to autoregulate during a hypoperfusion challenge.
Despite potential vasodilator effects of brain vessels by the parasympathetic nervous
system, via mediators such as vasoactive intestinal peptide, acetylcholine and nitric
oxide, current literature states that the parasympathetic nervous system does not play a
relevant role in cerebral autoregulation.24 However, our data presents an alternative
theory. Post-hoc analysis of spectral domain patterns reveal that, despite evidence of
sympathetic activity at the level of the heart and the periphery, the low-frequency to high
frequency ratio (which correlates with relative sympathetic activity) at the level of the
TCD declined from Base to Sympt. This decreased LF/HF ratio implies a sympathetic
withdrawal and a potential parasympathetic increase in power. Our results may be
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consistent with cholinergically-mediated oscillatory control (COCVASC) previously
described in the forehead microvasculature.3, 4 This cholinergically-mediated homeostatic
mechanism may increase compliance to allow a relatively greater percentage of the stroke
volume into the cranial circulation and thereby maintain TCD systolic values.
The HRV LF/HF trended upward between Baseline and Presympt indicating an increase
in sympathetic power in each subject group, except in the asymptomatic subjects,
however the changes were not statistically significant. This trend is plausible
physiologically because it represents compensation for perceived blood loss with
sympathetic activation. Then, in each group except asymptomatic, the HRV LF/HF
tended to decline at the time of Sympt, indicating a sympathetic withdrawal, or the
autonomic system’s inability to continue compensating for the cardiovascular insult, but
this also did not reach statistical significance. Sympathetic withdrawal at the time of
cardiovascular decompensation is well documented.11 In the asymptomatic subjects, HRV
LF/HF remained steady through Presympt and then increased significantly between
Presympt and Sympt. The increase in HRV LF/HF at the point of Sympt in this group is
logical because the individuals are not actually symptomatic. The subjects in the
asymptomatic group continued to mount a sympathetic response to the induced
hypovolemia at the point when a safety cutoff for blood pressure was reached. The HRV
LF/HF returned to Baseline values during recovery in all groups.
In lightheaded subjects, Forehead LD average change from baseline to Presympt for LF
power was +34.4%±81.3%; the change for HF power was +139.3±115.8% (p=0.027 by
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two-tailed paired t-test). Oscillatory activity at the HF (parasympathetic frequency)
appears to have been generated at the level of the forehead microvasculature, as the
oscillatory activity in the middle cerebral artery (as measured with transcranial Doppler)
showed a predominance of sympathetic activity at Base as well as Presympt. The TCD
did not demonstrate an increase in parasympathetic activity until the onset of symptoms.
We propose a homeostatic mechanism that occurs at all levels of the circulation from the
parasympathetic control of the microcirculation to the parasympathetic oscillations in
larger vessels (i.e. MCA) and vagal control systemically. In response to simulated
hypovolemia, the microvasculature of the forehead has an increase in HF
(parasympathetic) activity that is distinct from the predominantly LF activation
throughout the body. This may contribute to autoregulation and cerebral protection.
The present data also confirmed that serial advancement of overlapping windows with
JTFA significantly improves the temporal resolution of spectral-domain analysis in the
presence of an acute challenge. JTFA more effectively delineated the intermediate
frequency response of the forehead microvasculature, such that the LBNP-induced
increase in power delineated by JTFA was significantly greater than that delineated by a
traditional APSD. The improved temporal resolution of JTFA likewise identified
significant changes in the R-R interval power spectrum (HRV). These findings suggest
that JTFA should prove to be especially helpful when one is unsure as to when a
challenge will occur and as to the time course of brief homeostatic and therapeutic
responses.
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Limitations:
Statistical analysis of the subgroup data is challenging because of the limited number of
subjects enrolled in the study. It is difficult to prove differences between groups when
only two subjects remained asymptomatic. It was determined during the analysis that
Subject H (asymptomatic) could actually be skewing the data because of his groin pain.
Perhaps his sympathetic activation because of groin pain increased the LF/HF ratio in the
HRV analysis and also increased the LF power in all of the spectral analyses. It is
possible that he would have become symptomatic during the same progression of LBNP
had he been more comfortable. Future analyses of this data of may exclude Subject H
because of his pain.
We make the assumption that autonomic activity at the level of the microcirculation,
middle cerebral artery, or finger has implications for the autonomic status of the entire
body.53 It is possible that baroreceptor activity, or some other factors not related to the
autonomic nervous system, might affect the vasculature in the frequency ranges studied.53
The respiratory rate was not controlled in this study, leading to potential complications in
data interpretation. The respiratory frequency should be analyzed using JTFA and
compared to the TCD, Forehead LD and HRV power spectra to evaluate overlap of the
respiratory power with our frequency bands of interest (HF = 0.125 – 0.200). Forehead
LD and TCD require complex signal interpretation. TCD also has many limitations (as
mentioned previously), including a steep learning curve before technical proficiency is
gained. Forehead LD and TCD are both affected significantly by movement during the
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study. Both tools are costly and fragile, limiting the general utilization of the techniques
in the clinical setting.
Summary:
This investigation into the significance of the high-frequency oscillations in the forehead
microvasculature during hypoperfusion induced by LBNP demonstrated a potential
homeostatic mechanism. The preservation of blood flow in the forehead microvasculature
at the Presympt phase was accompanied by an increase in HF oscillations that was four
times the increase in LF power. The body exhibits primarily sympathetic tone (greater LF
than HF), at the time when HF increased at the forehead LD. An increase in
parasympathetic (HF) activity would lead to vasodilation and decreased resistance. This
decreased downstream resistance provides a mechanism for increased cerebral perfusion
gradient and therefore increased cerebral blood flow. When the oscillations cease, the HF
power diminishes, and then the resistance increases and the cerebral blood flow velocity
decreases and symptoms occur.
These findings have important clinical ramifications. Forehead LD has potential use in
intensive care units and emergency departments for patients whose mental status is
compromised (i.e. intubation, head injury), and for whom there is concern for
hemodynamic decompensation. A monitor that could predict cardiovascular collapse and
allow for earlier intervention would be invaluable. Conversely, in patients known to be
undergoing a vasoconstrictive challenge, forehead LD could provide information about
the integrity of their autonomic nervous function4 (i.e. in diabetic, hypertensive, or
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atherosclerotic patients). Additionally, HRV functions as a tool by which mortality can be
predicted after a myocardial infarction or during progressive heart failure.53 If forehead
LD is a similar marker of autonomic function, its predictive value may be equal to that of
HRV. Finally, because of the common vascular supply and neural innervation, the
forehead microvasculature may act as a surrogate for the cerebral microcirculation and
forehead LD could be a useful tool for monitoring cerebral perfusion during stroke,
subarachnoid hemorrhage, head injury, surgery (including carotid endarterectomy) and
many more clinical settings.
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